Eisai (company)

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Eisai" company – news · newspapers · books · scholar · JSTOR (January 2018) (Learn how and when to remove this message) You can help expand this article with text translated from the corresponding article in Japanese. (March 2020) Click [show] for important translation instructions. View a machine-translated version of the Japanese article. Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Consider adding a topic to this template: there are already 1,268 articles in the main category, and specifying|topic= will aid in categorization. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Japanese Wikipedia article at [[:ja:エーザイ]]; see its history for attribution. You may also add the template {{Translated|ja|エーザイ}} to the talk page. For more guidance, see Wikipedia:Translation. (Learn how and when to remove this message)

Eisai Co., Ltd.

Native name	エーザイ株式会社
Romanized name	Ēzai kabushiki gaisha
Company type	Public KK
Traded as	TYO: 4523 TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component
Industry	Pharmaceuticals
Founded	December 6, 1941; 82 years ago (1941-12-06)
Founder	Toyoji Naito
Headquarters	4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
Key people	Haruo Naito (President and CEO)
Products	Lecanemab Lenvema Halaven Aricept Pariet Banzel Zonegran Fycompa Zebinix
Revenue	¥ 741.8 billion (2023)[1]
Operating income	¥ 53.4 billion (2023)[1]
Net income	¥ 43.8 billion (2023)[1]
Total assets	¥ 743.9 billion (2023)[1]
Total equity	¥ 430.2 billion (2023)[1]
Owner	The Master Trust Bank of Japan (11.78%) Japan Trustee Services Bank (10.99%) Nippon Life (4.29%)[2]
Number of employees	10,000 (2023)[1]
Website	Official website
Footnotes / references [2] [1]

Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.^[3]